Khasaeva M A, Gorokhova T V, Boĭko A N, Gusev E I
Zh Nevrol Psikhiatr Im S S Korsakova. 2013;113(2 Pt 2):87-92.
Recently published results of II and II phase clinical trials of alemtuzumab in relapsing-remitting multiple sclerosis (MS) are reviewed. This drug has an immunosuppressive mechanism of action with an anti-inflammatory effect higher than that of high-dose beta-interferon. Its neuroprotective activity and possible side-effects are discussed.
